At the Retina Society meeting held in Chicago, Illinois, Christine N. Kay, MD a vitreoretinal surgeon and IRD specialist from Gainesville, Florida, presented research on MCO-010, a novel optogenetic ...

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients. Marion Munk, MD, PhD, talked with Modern Retina® during the ...

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025. Maria Berrocal, MD, met up with Modern Retina® during the 2025 European Society of Retina Specialists (EURETINA) congress ...

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS ...

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space. Modern imaging technologies, like advanced forms of optical coherence ...

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists. The 2025 European Society of Retina ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

The European Commission (EC) has granted marketing authorization for EYLUXVI (ALT-L9), an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics. 1 EYLUXVI is ...

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies. The US Food and Drug Administration (FDA) has granted Priority Review to Chiesi Global ...

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment. Kalaris Therapeutics announced the company ...

Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD. Luxa is a clinical-stage biotechnology ...